Hepatic SIRT1 expression is reduced in different animal models of NAFLD, and loss of SIRT1 in hepatocytes leads to the development of hepatic steatosis and inflammation while on an HFD32, 33, suggesting that pharmacological activation of SIRT1 may constitute a potential therapeutic strategy. Here, SIRT1 is linked to metabolic dysfunction-associated steatotic liver disease.